


## Phenylbiguanide

Cat. No.:	HY-101331		
CAS No.:	102-02-3		
Molecular Formula:	C <sub>8</sub> H <sub>11</sub> N <sub>5</sub>		
Molecular Weight:	177.21		
Target:	5-HT Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 150 mg/mL (846.45 mM; Need ultrasonic)  
 H<sub>2</sub>O : ≥ 25 mg/mL (141.08 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	5.6430 mL	28.2151 mL	56.4302 mL
	5 mM	1.1286 mL	5.6430 mL	11.2860 mL
	10 mM	0.5643 mL	2.8215 mL	5.6430 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (14.11 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (14.11 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (14.11 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Phenylbiguanide is a 5-HT<sub>3</sub> receptor selective agonist with an EC<sub>50</sub> of 3.0±0.1 μM.

#### IC<sub>50</sub> & Target

5-HT<sub>3</sub> Receptor  
3 μM (EC<sub>50</sub>)

<b>In Vitro</b>	<p>Phenylbiguanide (1-Phenylbiguanide) is a 5-HT<sub>3</sub> receptor selective agonist with pEC<sub>50</sub>s of 5.57, 4.07, and 4.47 for r5-HT<sub>3A(b)</sub>, h5-HT<sub>3A</sub>, m5-HT<sub>3A(b)</sub>, respectively<sup>[1]</sup>. The effect of Phenylbiguanide (1-Phenylbiguanide hydrochloride) in promoting the growth of the HT29 cell line is investigated. Phenylbiguanide causes a dose dependent proliferation of HT29 cells after 48 hours incubation. The maximum proliferation is at a 5HT concentration of 12.5 μM (P≤0.01). Phenylbiguanide significantly stimulates the growth of cells at concentrations of 3.125 μM (P≤0.05) and 6.25 μM (P≤0.01)<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>In Vivo</b>	<p>In anaesthetised mice, Phenylbiguanide (PBG), a drug that is known to stimulate cardiopulmonary afferent C-fibres, is injected into the right atrium of the heart and mapped c-Fos expression within specific regions of the central nervous system. Intraatrial injection of PBG produces a reflex cardiorespiratory response including a pronounced bradycardia and a respiratory depression<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## PROTOCOL

<b>Cell Assay</b> <sup>[2]</sup>	<p>HT29 cells are washed with Phosphate buffer saline (PBS) and harvested with a 0.5% trypsin solution at 50-60% confluency. Cells are then added to wells at a density of 104 cells/well in a 96-well plate to a final volume of 100 μL/well. After 24 hours of incubation at 37°C in a 5% CO<sub>2</sub> atmosphere, the culture medium is replaced with 200 μL fresh culture medium containing 5HT hydrochloride, Phenylbiguanide hydrochloride at concentrations of: 3.125, 6.25, 12.5, 25, 50, and 100 μM. Cells cultured solely in media served as negative controls. After 48 hours of incubation at 37°C in a 5% CO<sub>2</sub> atmosphere, the culture medium is removed and 8 μL MTT reagent (diluted in PBS at a concentration of 4 mg/mL) is added to 50 μL of fresh culture medium at a final concentration of 0.55 mg/mL. The optimum incubation period time is determined in a pilot study<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>Animal Administration</b> <sup>[3]</sup>	<p>Mice<sup>[3]</sup></p> <p>Adult male specified pathogen free (SPF) BALB/c mice (28-33 g; n=10) are used throughout this study. All mice have free access to water and food in a light (12: 12 h light/ dark cycle, lights on at 0700 h) and temperature-controlled (21-23°C) environment. Mice are randomly assigned to two treatment groups, 1) intra-atrial injection of 0.9% saline (controls, n=5) or 2) intra-atrial injection of vehicle containing Phenylbiguanide (n=5). For the PBG injected group, mice are injected with an effective dose of Phenylbiguanide (1-1.5 μg in 10-15 μL saline). This is repeated five times in total with each injection separated by 8-10 min. For control mice, each mouse receives five saline injections (10-15 μL each), also at 8-10 min intervals<sup>[3]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

## REFERENCES

- [1]. Mair ID, et al. Pharmacological characterization of a rat 5-hydroxytryptamine type3 receptor subunit (r5-HT<sub>3A(b)</sub>) expressed in *Xenopus laevis* oocytes. *Br J Pharmacol*. 1998 Aug;124(8):1667-74.
- [2]. Ataee R, et al. Study of 5HT3 and HT4 receptor expression in HT29 cell line and human colon adenocarcinoma tissues. *Arch Iran Med*. 2010 Mar;13(2):120-5.
- [3]. de Vries A, et al. Characterisation of c-Fos expression in the central nervous system of mice following right atrial injections of the 5-HT3 receptor agonist Phenylbiguanide. *Auton Neurosci*. 2005 Dec 30;123(1-2):62-75.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA